Abstract
Many complications related to silicone implants have been reported recently, from clinical symptoms manifestations to association with some specific types of cancer. During the early 2010s, it was believed that implants were biocompatible and inert to the human body and that gel bleeding/leakage events were rare and without repercussions for the human body. However, at the end of 2010s, several studies pointed out that gel bleeding was more frequent than previously believed, and the pathogenic potential of free silicone should not be ignored. The Food and Drug Administration recommends performing magnetic resonance imaging in asymptomatic patients 5–6 years after implant placement. The descriptors in the Breast Imaging and Reporting Data System lexicon seem outdated for classifying the new generations of implants with cohesive gel, which hinders the diagnosis of device complications. In this review, supported by our research data publications related to silicone implants for 6 years on a prospective study protocol, most of them being original articles, we summarized the main complications observed in clinical practice and discuss the impact of these changes on patients’ outcomes focusing on the pericapsular space. Many complications related to silicone implants have been reported recently, from clinical symptoms manifestations to association with some specific types of cancer, such as breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) and breast implant–associated squamous cell carcinoma (BIA-SCC), both recognized by the Food and Drug Administration (FDA) agency (1–4). Since the end of breast implants moratorium at the beginning of the 21st century, the number of surgeries using silicone implants has increased exponentially. Patients opt for these devices for augmentation surgery for esthetic purposes or reconstructive surgeries for breast cancer treatment (5). During the early 2010s, it was believed that implants were biocompatible and inert to the human body and that gel bleeding/leakage events were rare and without repercussions for the human body (6). However, at the end of 2010s, several studies pointed out that gel bleeding was more frequent than previously believed and the pathogenic potential of free silicone should not be ignored (7, 8). At the same time, groups of women gathered on social networks associating their morbidities with the presence of breast silicone implants and called the disease as breast implant illness (BII) (9–11). Many recently published manuscripts link the pathogenic potential of silicone with the chronic inflammation promoted by the foreign body (12, 13). One of the main complaints of patients with clinical symptoms related to silicone implants is the difficulty in diagnosing the disease. The FDA recommends performing magnetic resonance imaging (MRI) in asymptomatic patients 5–6 years after implant placement and an ultrasound scan for patients referred for diagnostic tests (14). Nevertheless, imaging exams follow the recommendations proposed by the American College of Radiology (ACR), incorporated in the Breast Imaging and Reporting Data System (BI-RADS) lexicon 5th edition in a specific chapter. The descriptors in the BI-RADS lexicon seem outdated for classifying the new generation of implants with cohesive gel, which hinders the diagnosis of device complications (15). The lexicon is practically limited to evaluating the integrity of silicone implants, extracapsular ruptures, and intracapsular collection. The lexicon does not present guidelines for evaluating the pericapsular tissue nor lists the possible descriptors compatible with cohesive gel complications (15). In this review, supported by our research data publications related to silicone implants for 6 years on a prospective study protocol, most of them being original articles, we summarized the main complications observed in clinical practice and discuss the impact of these changes on patients’ outcomes focusing on the pericapsular space. Silicone implants are medical devices approved by the FDA for medical use and included in category III devices. The FDA describes category III as “usually sustain or support life, are implanted or present a potential unreasonable risk of illness or injury” (16). The implants are composed of polydimethylsiloxane polymers in long and short chains. The most stiff state is in the implant shell and the softest in the inner gel. The latest generation of implants consists of cohesive gels that determine greater product stability. After implant placement, a fibrous capsule forms around it to protect the host from the foreign body. The fibrous capsule is composed of defense cells, including macrophages and lymphocytes (17–19). Over time, there is degradation on the implant's surface, which determines changes in the shell permeability that allows leakage of the internal content. Studies demonstrate that shorter-chain silicones have more potential for leakage and distant migration. A 2020 study indicates the presence of silicone inside the fibrous capsule and in the pericapsular tissue in 98.8% and 86.6%, respectively. The study also divided the patients into two groups, one with cohesive gel and the other with other types of gel. The study results showed no statistically significant difference for extravasation between groups (20). When in contact with the fibrous capsule, the silicone particles arising from the degradation/leakage of the device activate the macrophage–antigen complex (MAC). MAC activation will recruit T lymphocytes against the foreign body. Silicone particles in this situation appear in two patterns. The first is extracellular silicone, where giant cells formed around the silicone, associated with intense fibrosis, resulting in a silicone-induced granuloma, described as silicone-induced granuloma of breast implant capsule (SIGBIC). In the second form, which is more related to acute conditions, the silicone phagocytosis by the macrophage is frustrated and results in the macrophage's apoptosis. This process determines the deregulation and perpetuation of the immune response with excessive consumption of lymphocytes. In these cases, the inflammatory process produces exudate (21). Based on our observations, we linked the exudate resulting from the dysregulated inflammatory process with the intracapsular formation of late seroma and hematoma. Lymphocyte consumption may be the reason for the statement by Keane et al. (22) published in a review: “Curiously, a relative attenuation of circulating T-helper cells may occur in the first couple days following placement of a textured, but not smooth breast implant. While each of these studies proposes a different ‘trigger’, chronic inflammation is the common thread and is the most likely facilitator of malignant transformation to BIA-ALCL.” Despite the original article demonstrating more significant postoperative leukopenia in patients with textured implants when compared with smooth implants (23), we published a case report of BIA-ALCL in a patient who had SIGBIC and signs of gel bleeding in both breasts, with leukopenia in preoperative exams. In the postoperative period of the en bloc capsulectomy, there was normalization of leukocyte levels in peripheral blood (24). According to the BI-RADS lexicon, the MRI may report two implant locations. The first is retroglandular placement, where the implant is anterior to the pectoralis muscle, and second is retropectoral placement, deep into the pectoralis muscle (15). The site for the implant placement decision is shared between the surgeon and the patient. Implant locations have advantages and disadvantages that must be evaluated before surgery. Retroglandular surgery is less complicated, with fewer postoperative complications but less satisfactory esthetic results. Conversely, retropectoral placement has a more complex surgical time, with postoperative complications and a more satisfactory esthetic result. The retropectoral site is recommended for breast cancer screening because it has a smaller area of the penumbra (overlap of the implant over the breast parenchyma) than the retroglandular site (15, 25, 26). The association between silicone implants and breast neoplasms is quite controversial. Few studies in the literature discuss the topic. The FDA recognizes two implant-related malignancies, BIA-ALCL and BIA-SCC. However, numerous case reports linking implants with neoplasms are found in digital medical libraries, such as angiosarcoma. There are also reports of fibromatosis originating from the silicone implant placement. Studies in the literature converge on the difficulty of determining the triggering factor for these neoplasms’ development (27–29). In a 2021 study, our group published a theory that chronic and persistent inflammation resulting from breast implant placement could be the main factor in determining metaplasia and dysplasia of cells exposed to the chronic inflammatory process (30). We also published a case report that shows evidence of areas of silicone leakage with the appearance of breast neoplasms, with a benign papillary lesion diagnosis (31). The studied tumor's origins were closely linked to the areas of exposure to the silicone gel. Tumors arising from an inflammatory process are nothing new in medicine. This category includes cervix cancer and human papillomatosis virus (HPV), basal cell cancer and sun exposure, esophageal cancer from chronic reflux, and Barrett's metaplasia (30). The FDA recommends MRI as the imaging modality of choice for diagnosing and screening implant-related complications (16). Ultrasonography can be an alternative due to its wide availability, but its low reproducibility is the main limiting factor. The BI-RADS lexicon used to describe changes in the breast has a specific chapter for evaluating implants. The lexicon is restricted to classifying implants according to type, location, intracapsular rupture diagnosis, and extracapsular silicone presence. The lexicon was launched in 2013 when non-cohesive gel implants were prevalent (15). Descriptors related to the cohesive gel are not described by the lexicon, which makes their descriptors outdated. Since 2017, our group has started a research protocol to evaluate silicone implants. Among the findings described, the ability of magnetic resonance imaging to detect gel bleeding stands out. The finding of gel bleeding on MRI was described as SIGBIC. SIGBIC is a gel bleeding marker, whose descriptor is “intracapsular heterogeneous tissue with late contrast enhancement compatible to silicone-induced granuloma” (32). In 2021, we published a magnetic resonance classification proposal for fibrous capsules, divided into four evolutionary categories, with category 4 representing changes indicative of a pericapsular inflammatory process. The classification graduates the degree of fibrous capsule impairment and the association with an acute inflammatory process (33) (Figure 1). Figure 1. A 58-year-old woman with silicone implants for 6 years, with suspicion of right capsular contracture. The multiplanar intensity projection (MIP) reconstruction (A), the axial post-contrast image (B), and the flow intensity image (C) show capsular contracture with inflammatory signs in the right breast (yellow arrows). The green arrows show non-mass enhancement of the pericapsular tissue, especially in the right breast. The right implant is an example of fibrous capsule grade 4 and the left as a grade 3. The pericapsular space can be divided according to the structures that compose it. In a didactic way, we divided the pericapsular space into (1) thoracic wall, (2) connective tissue, (3) fibroglandular tissue, and (4) skin (Figure 2). Figure 2. Illustration of breast compartments and structures to be evaluated in breast MRI. The chest wall will usually meet the posterior surface of the silicone implants. In this topography, implant closure seals are usually found and serve as a reference for diagnosing rotation. The closing seal is important because it is the area of most significant silicone leakage, with direct exposure of the silicone to the fibrous capsule (Figure 3). In a review by Keane et al. (22), the authors stated intraoperative findings of BIA-SCC that include fungating breast capsule masses with granulomatous and keratinized debris contained within a viscous, turbid seroma fluid. The article also discussed that the malignancy arises from the posterior aspect of the implant capsule. Curiously, the tumor grew in the same topography reported in our manuscript, where we describe a patient that developed breast carcinoma at the site of silicone exposure in the closing seal defect (30). Figure 3. Apparent intact smooth silicone implant (A). The posterior seal before (B) and after (C) compression shows discontinuity of the seal with exposure to the internal cohesive gel content (C). In the retroglandular plane, the fibrous capsule is in close contact with the pectoral muscle. Chronic inflammation of the fibrous capsule can cause contiguity to invade the pectoral muscle, making it difficult to perform an en bloc capsulectomy. Sometimes it is required to remove the superficial fibers of the compromised muscle with the diseased fibrous capsule. In the retropectoral plane, the implant is located between the pectoral muscle and the chest wall. The device promotes pectoral muscle stretching and compresses the chest wall. Over time, the pectoral muscle becomes atrophic, as does the intercostal musculature. These muscles’ atrophy favors implant herniation into the intercostal spaces. In this context, the combination of a thickened capsule, implant herniation into the intercostal space, and atrophy of the intercostal muscles result in proximity between the fibrous capsule and the thoracic cavity, sometimes encountering the parietal pleura. These processes related to thoracic muscle atrophy and the presence of a foreign body may hinder thoracic expansion (Figure 4). Many patients report significant improvement in respiratory capacity in the immediate postoperative period of explant surgery. Figure 4. A 28-year-old woman with esthetic retropectoral silicone for 4 years (A,B), and a 55-year-old woman with a reconstructive surgery of the right breast for years. Axial T2** image (A) and sagittal proton density image (B) show a subpectoral bilateral implant. The yellow arrows show the herniation of the implant surface to the intercostal space. Atrophy of the intercostal muscle and thickening of the fibrous capsule in contact with the parietal pleura are observed. Axial post-contrast image (C) and sagittal proton density image (D) show capsular contracture associated with pericapsular edema. The extension of the enhancement to the parietal pleura is also observed (green arrow). Measuring the distance between the fibrous capsule and the parietal pleura in retropectoral implants may be necessary for the surgical programming of implant removal to minimize intraoperative complications. We generally value measurements with distances smaller than 0.5 cm. In episodes of recurrent/remitting acute inflammation, the established chronic inflammatory process can extend to the thoracic wall structures, involving the ribs, intercostal musculature, and costosternal joints. Magnetic resonance imaging is the best method to assess the involvement of the chest wall and allows for distinguishing the compromised structures by the inflammatory process (Figure 5). The differential diagnosis in this situation is malignant neoplasia, especially sarcomas and desmoid tumors, thus having the convenience to continue the clinical investigation in the presence of a pericapsular inflammatory process of the chest wall (27, 28). Figure 5. A 48-year-old woman with reconstructive retropectoral silicone for 6 years. Axial T1 post-contrast image (A) and sagittal T1 post-contrast images at different sites (B,C) show a left capsular contracture associated with edema (yellow arrow). There is contiguity of the fibrous capsule to the pectoral muscle (green arrow) and the skin (blue arrow). The inflammatory process also extends to the thoracic wall, involving the ribs and intercostal muscles. The connective tissue of the breasts is formed essentially by fat, especially over the years when fibroglandular tissue is replaced by adipose tissue. Mesenchymal cells and fibroblasts, blood vessels, lymphatic system, and nervous system cells are also present. Acute inflammation of the fibrous capsule usually determines edema, architectural distortions, and atypical enhancement of the pericapsular tissue on magnetic resonance imaging. In these cases, it is possible to observe the thickening and enhancement of the fibrous capsule compatible with capsular contracture associated with the pericapsular tissue impairment. The degree of impairment and extension will depend on the intensity of the inflammatory process. Steatonecrosis is most frequently associated with post-surgical complications of silicone implants. The clinical complaints are variable and depend on the tissue involvement extension (34, 35). Steatonecrosis often manifests as palpable, hardened masses, which may be associated with breast edema. Pericapsular steatonecrosis with acute inflammatory signs should be categorized as BI-RADS 4 because they are new and developing (Figure 6). Figure 6. A 71-year-old woman with breast reconstructive surgery with implants for 5 years, presenting with a palpable mass in the medial quadrant. Sagittal proton density image (A), axial post-contrast imaging (B), axial T2** sequence (C), and ultrasonography show a heterogeneous mass with fat content and moderate enhancement, associated with skin thickening and without cleavage plan with the pectoral muscle. The ultrasound (D) shows a vascularized heterogeneous mass. The biopsy diagnosis was steatonecrosis. The first neoplasm recognized as originating from silicone implants was BIA-ALCL. BIA-ALCL expresses monoclonal proliferation of T lymphocytes, with CD30-positive and ALK-negative markers. ALK is a lymphoma marker, and, as it is negative, there are questions regarding the classification of BIA-ALCL as a true lymphoma (2). In the literature, there are reports of patients with spontaneous remission of BIA-ALCL from diagnosis to surgical excision without specific treatment (36). Compromise of the pericapsular space in cases of BIA-ALCL is uncommon. According to the 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of BIA-ALCL, when the lesion invades the pericapsular space, it should be considered as stage 4 according to the TNM criteria (37). In our experience, we had a case of spontaneous remission of extracapsular involvement in a patient who refused to undergo adjuvant chemotherapy after BIA-ALCL diagnosis in explant surgery. In the follow-up exams, there was spontaneous remission of the residual lesion by PET-CT in a 3-year interval. Recently, some cases of breast implant–associated diffuse large B-cell lymphoma (BIA-DLBCL) have been reported in the medical literature. BIA-DLBCL is composed of cellular heterogeneity where the presence of giant B cells stands out. Some studies associate BIA-DLBCL with Epstein–Barr virus (38–40). Magnetic resonance imaging is the method of choice for diagnosing BIA-ALCL and BIA-DLBCL, and it is worth noting that any new lesion compromising the pericapsular environment and presenting contrast enhancement should be considered suspicious. The enhancement of these lesions indicates cellular metabolic activity (Figure 7). Figure 7. A 47-year-old woman with a palpable lump in the right breast. The sagittal proton density image (A),...

This publication has 43 references indexed in Scilit: